In 2020, the National Academies of Science confirmed the unreliability of compounded bioidentical hormones (cBHT). After 21 months of data collection and analysis, the investigating committee concluded: “Given the paucity of data on the safety and effectiveness of cBHT… there is insufficient evidence to support the overall clinical utility of cBHT as treatment for menopause.”